T1	Participants 85 132	very platinum-sensitive ovarian cancer patients
T2	Participants 234 342	patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial
T3	Participants 149 196	subset analysis of the CALYPSO phase III trial.
T4	Participants 369 525	international non-inferiority trial enrolled women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies
T5	Participants 708 737	patients with a TFI>24 months
T6	Participants 886 959	259 very platinum-sensitive patients were included (n=131, CD; n=128, CP)
T7	Participants 1819 1861	patients with very platinum-sensitive ROC.
